Immune Biomarkers in the Prediction of Future Myocardial Infarctions in People With Human Immunodeficiency Virus

Janine M Trevillyan; Carlee Moser; Judith S Currier; Tamer Sallam

doi:10.1093/cid/ciz765

Immune Biomarkers in the Prediction of Future Myocardial Infarctions in People With Human Immunodeficiency Virus

Clin Infect Dis. 2020 Apr 10;70(8):1764-1767. doi: 10.1093/cid/ciz765.

Authors

Janine M Trevillyan^{1

2}, Carlee Moser³, Judith S Currier¹, Tamer Sallam⁴

Affiliations

¹ Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles.
² Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Australia.
³ Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
⁴ Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles.

Abstract

In a retrospective case control analysis, following adjustments for high-sensitivity C-reactive protein (hsCRP), traditional cardiovascular risk factors, and the CD4/CD8 T-cell ratio, higher lipopolysaccharide-binding protein (LBP) was associated with future myocardial infarctions in hsCRP human immunodeficiency virus (HIV). LBP may be a marker of cardiovascular risk with utility in HIV.

Keywords: HIV; acute myocardial infarction; cardiovascular disease; immune activation; inflammation.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Biomarkers
C-Reactive Protein / analysis
HIV
HIV Infections* / complications
Humans
Myocardial Infarction*
Retrospective Studies

Substances

Biomarkers
C-Reactive Protein

Abstract

Publication types

MeSH terms

Substances

Grants and funding